SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today released its Appendix 4C for the consolidated Group for the third quarter of FY 2020.
During the quarter, Dr Michael Baker commenced as CEO and on the 9th of March, SUDA also appointed a General Manager for the Perth operations, Tony Macintyre. Dr Baker commented “It is very pleasing to find an individual with such a strong technical, operations and regulatory background. We are delighted that Tony has joined the team at SUDA.”
For further information, please download the attached PDF:
Download this document